About the job
ABOUT US
At Invivyd, Inc., we are dedicated to protecting the over 9 million immunocompromised individuals in the United States, including those most vulnerable to severe COVID-19. Our mission is to combat serious viral infectious diseases, starting with SARS-CoV-2, utilizing our proprietary technology platform to develop leading-edge antibody therapies.
In March 2024, Invivyd received Emergency Use Authorization (EUA) from the U.S. FDA for a monoclonal antibody in our innovative pipeline. Following this, in October 2025, we advanced our REVOLUTION clinical program for VYD2311, a vaccine alternative monoclonal antibody.
Join us in making a significant impact in the field of infectious disease care. Be part of Invivyd.

